<DOC>
	<DOCNO>NCT01326767</DOCNO>
	<brief_summary>This study perform grade IIIb grade IV Non Small Cell Lung Cancer ( NSCLC ) chemotherapy naive patient good performance status . In course study , patient treat Paclitaxel combination either Cisplatin Carboplatin maximum six therapy cycle . The goal study determine , pharmakokinetic driven dose adaptation paclitaxel lead reduction grade 4 neutropenia , compare conventional Paclitaxel dosing , without affect progression free survival overall survival . This study include biomarker analysis optional genetic substudy .</brief_summary>
	<brief_title>Central European Society Anticancer Research ( CESAR ) Study Paclitaxel Therapeutic Drug Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Capable understanding protocol requirement risk , provide write informed consent . Patients histologically confirm NSCLC ( stage IIIBIV ) . Patients consider firstline palliative chemotherapy paclitaxel combination either cisplatin carboplatin . Patients receive prior adjuvant non taxanecontaining adjuvant chemotherapy eligible . At least one bidimensionally measurable lesion accord RECIST 1.1 . ECOG Performance Status ( ECOGPS ) status ≤ 2 . Female male patient 18 75 year age randomization Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use acceptable contraceptive method ( intrauterine device [ IUD ] , oral contraceptive double barrier device ) , must negative serum pregnancy test within 1 week prior begin treatment trial . Nursing patient exclude . Sexually active men must also use acceptable contraceptive method ( condom ) . An absolute neutrophil count &gt; 1,500 cells/ mm3 ( = 1.5 G/l ) . Platelet count &gt; 100,000/mm3 . Total bilirubin ≤ 2 x upper limit normal . AST ALT ≤ 2.5 x upper limit normal , ≤ 5 x upper limit normal case liver metastasis . Creatinine clearance ( accord CockcroftGault formula ) ≥30ml/min . For patient plan receive Cisplatin : Creatinine clearance ≥60ml/min . Patients suffer asymptomatic brain metastasis enrol case corticosteroid therapy indicate . Prior irradiation must complete least 4 week prior first cycle treatment . Serious concomitant systemic disorder ( e.g. , active infection , severe heart disease , uncontrolled hypertension diabetes mellitus ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study . A history hypersensitivity reaction drug formulate polyoxyethylated castor oil . Having receive prior treatment paclitaxel cisplatin carboplatin ( drugs/drug combination allow ) . Concomitant treatment target drug ( licensed experimental ) like bevacizumab cetuximab . Any condition / concomitant disease allow chemotherapy paclitaxel , platinum compound ( carboplatin cisplatin ) require premedication treatment regimen . Pregnant/nursing woman . Individuals know seropositive human immunodeficiency virus , hepatitis C virus , hepatitis B surface antigen syphilis . Treatment cytotoxic biologic agent experimental drug within 4 week prior begin treatment study . Secondary malignancy within last five year , exception adequately treat carcinomainsitu uterine cervix , basalcell carcinoma skin pTa pTis urothelial cancer . Medical psychological condition would permit patient complete study sign inform consent . Preexisting neuropathy &gt; grade I NCICTC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>